NCT07062848An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.

N/A

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Achondroplasia

N/A

Clinical Trials (1)

NCT04035811Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

N/A

99mTc-pyrophosphate Scintigraphy

Transthyretin Amyloidosis

N/A

Clinical Trials (1)

NCT05577819Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

N/A

ADH1 and ADH2 Disease Monitoring Study (DMS)

Autosomal Dominant Hypocalcemia

N/A

Clinical Trials (1)

NCT05227287ADH1 and ADH2 Disease Monitoring Study (DMS)

N/A

BBP-711

Healthy

Phase 1

Clinical Trials (1)

NCT04876924A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers

Phase 1

BBP-671

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04836494A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia

Phase 1

Infigratinib

Glioma

Phase 1

Clinical Trials (1)

NCT04424966Infigratinib in Recurrent High-Grade Glioma Patients

Phase 1

Infigratinib

Breast Cancer

Phase 1

Clinical Trials (1)

NCT04504331Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Phase 1

acoramidis

Amyloidosis

Phase 1

Clinical Trials (1)

NCT04769479A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects

Phase 1

Infigratinib

Bladder Transitional Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT04972253Phase I BLASST-3 Trial

Phase 1

BBP-398

Tumor, Solid

Phase 1

Clinical Trials (1)

NCT04528836First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Phase 1

AG10 oral tablet

Amyloid Cardiomyopathy, Transthyretin-Related

Phase 1

Clinical Trials (1)

NCT03294707Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

Phase 1

BBO-10203

Solid Tumor, Adult

Phase 1

Clinical Trials (1)

NCT06625775Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1

BBO-11818

Non-Small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT06917079BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1

BBO-8520

Non-small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT06343402Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Phase 1

BBP-398 with nivolumab

Non Small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT05375084SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Phase 1

BBP-398

Solid Tumor, Adult

Phase 1

Clinical Trials (1)

NCT05480865SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Phase 1

VT30

Venous Malformation

Phase 1/2

Clinical Trials (1)

NCT04409145First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

Phase 1/2

PTR-01

Recessive Dystrophic Epidermolysis Bullosa

Phase 2

Clinical Trials (1)

NCT05143190Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

Phase 2

Encaleret

Autosomal Dominant Hypocalcemia (ADH)

Phase 2

Clinical Trials (1)

NCT04581629Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

Phase 2

Infigratinib

Achondroplasia

Phase 2

Clinical Trials (1)

NCT05145010Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Phase 2

AG10

Amyloid Cardiomyopathy

Phase 2

Clinical Trials (1)

NCT03536767Open-Label Study of AG10 in Patients with Cardiomyopathy

Phase 2

BGJ398

Advanced Cholangiocarcinoma

Phase 2

Clinical Trials (1)

NCT02150967A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Phase 2

Infigratinib

Hypochondroplasia

Phase 2

Clinical Trials (1)

NCT07393373Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

Phase 2

Infigratinib is provided as a single dose of minitablets for oral administration

Achondroplasia

Phase 2

Clinical Trials (1)

NCT07169279Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

Phase 2

AG10

Familial ATTR-CM (ATTRm-CM, or FAC)

Phase 2

Clinical Trials (1)

NCT03458130Study of AG10 in Amyloid Cardiomyopathy

Phase 2

Infigratinib 0.016 mg/kg

Achondroplasia

Phase 2

Clinical Trials (1)

NCT04265651Study of Infigratinib in Children With Achondroplasia

Phase 2

infigratinib 0.128 mg/kg/day

Hypochondroplasia

Phase 2/3

Clinical Trials (1)

NCT06873035An Interventional Study of Infigratinib in Children With Hypochondroplasia

Phase 2/3

Encaleret

Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Phase 2/3

Clinical Trials (1)

NCT07080385Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Phase 2/3

Infigratinib

Upper Tract Urothelial Carcinomas

Phase 3

Clinical Trials (1)

NCT04197986Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Phase 3

Infigratinib 0.25 mg/kg/day

Achondroplasia

Phase 3

Clinical Trials (1)

NCT06164951A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

Phase 3

Acoramidis

Amyloidosis in Transthyretin (TTR)

Phase 3

Clinical Trials (1)

NCT07116473To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

Phase 3

Acoramidis

Amyloid Cardiomyopathy, Transthyretin-Related

Phase 3

Clinical Trials (1)

NCT04988386Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Phase 3

AG10

Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Phase 3

Clinical Trials (1)

NCT04418024Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

Phase 3

Acoramidis

Amyloidosis

Phase 3

Clinical Trials (1)

NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Phase 3

acoramidis

Amyloidosis

Phase 3

Clinical Trials (1)

NCT03860935Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Phase 3

BGJ398

Advanced Cholangiocarcinoma

Phase 3

Clinical Trials (1)

NCT03773302Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Phase 3

Encaleret

Autosomal Dominant Hypocalcemia (ADH)

Phase 3

Clinical Trials (2)

NCT05680818Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Phase 3

NCT05735015PTH-independent Effects of Encaleret

Phase 2

Acoramidis

Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Phase 3

Clinical Trials (1)

NCT04882735Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

Phase 3

ALXN2060

Symptomatic Transthyretin Amyloid Cardiomyopathy

Phase 3

Clinical Trials (1)

NCT04622046A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Phase 3

Open Jobs (69)

Interview Prep Quick Facts

Portfolio: 1 approved product, 44 clinical trials

Top TAs: Cardiovascular, Oncology, Neurology

Open Roles: 69 active jobs

Portfolio Health

Growth1 (100%)

1 total products

Therapeutic Area Focus

Cardiovascular

1 marketed8 pipeline

Oncology

9 pipeline

Neurology

4 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

BridgeBio Pharma

Products & Portfolio (1)

Pipeline & Clinical Trials

Open Jobs (69)

Manager/Sr. Manager, QC

Senior Clinical Trial Manager- Imaging Study

Associate Director/Director, Drug Product Manufacturing

MSL/Sr. MSL (Philly/Upstate NY)

Director, Insights & Forecasting, International

Junior Executive Assistant

Director ARD (MLB-Calci) - East

Chief of Staff to CEO of BridgeBio and GondolaBio

Director/Sr. Director, Vendor Quality Management

Senior Director, Commercial Excellence, International

Contracts Counsel

Director, State Government Affairs

Sr. Director Evidence Generation

Director, Federal Government Affairs (Democratic Lead)

Sr. Director / Exec. Director, Reg Affairs

Sr. Manager/Associate Director, Market Access Marketing (ML Bio)

Sr. Manager/Associate Director, Market Access Marketing (Calcilytix)

Associate Director/Director, Clinical FP&A

Director, People Business Partner

Associate Director/Director, Translational Biology

Associate Medical Director, Medical Affairs

Director, Market Access Western Europe Region

Area Sales Director - West

Senior Director, Market Access, Europe Central Region

Manager, QA Compliance

Hiring Trend